Immix Biopharma Announces Additional NXC-201 AL Amyloidosis
LOS ANGELES, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company...
Source: globenewswire.com
Page 3 - Nasdaq Immx News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nasdaq Immx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nasdaq Immx Today - Breaking & Trending Today
Short Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Increases By 8.2%
Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) saw a significant increase in short interest in July. As of July 31st, there was short interest totalling 59,300 shares, an increase of 8.2% from the July 15th total of 54,800 shares. Based on an average daily volume of 240,700 shares, the days-to-cover ratio is currently 0.2 […]
Source: wkrb13.com
Immix Biopharma Subsidiary Nexcella Announces NXC-201
Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory Multiple Myeloma will be presented in Athens September 27-30, 2023...
Source: globenewswire.com
Immix Biopharma (NASDAQ:IMMX) Stock Price Down 6.1%
Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) was down 6.1% during trading on Monday . The stock traded as low as $2.03 and last traded at $2.15. Approximately 478,451 shares changed hands during mid-day trading, an increase of 90% from the average daily volume of 252,189 shares. The stock had previously closed at $2.29. […]
Source: modernreaders.com
Immix Biopharma Subsidiary Nexcella Completes Pre-IND
LOS ANGELES, June 26, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), a...
Source: globenewswire.com